Clinical Trials
2 trialsNCT01991210 2017-08-21
A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)
Genentech, Inc.
Phase 2 Terminated
NCT01363947 2017-06-07
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer
Genentech, Inc.
Phase 1 Completed